Trial Profile

CLEVER Pilot Trial: A Phase II Pilot Trial of HydroxyChLoroquine, EVErolimus or the Combination for Prevention of Recurrent Breast Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 07 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Everolimus (Primary) ; Hydroxychloroquine (Primary)
Indications Early breast cancer; HER2 negative breast cancer; Triple negative breast cancer
Focus Adverse reactions; Therapeutic Use
Acronyms CLEVER

Most Recent Events

18 Dec 2023 New trial record
24 Oct 2023 Results investigating whether targeting dormancy through hydroxychloroquine , and/or everolimus in DTC+ BC survivors is feasible, presented at the 48th European Society for Medical Oncology Congress

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com